South Africa clears Phase 1 trial for Oramed oral COVID-19 vaccine


Oramed Pharmaceuticals’ (NASDAQ, TASE:ORMP) majority-owned subsidiary, Oravax Medical, received clearance from the South African Health Products Regulatory Authority to begin patient enrollment in a first-in- human, Phase 1 clinical trial, of its oral COVID-19 vaccine. Preparations to begin the trial are now underway.

Oravax’s virus-like particle (VLP) vaccine technology targets three SARS CoV-2 virus surface proteins, including proteins less susceptible to mutation, making the vaccine potentially more effective against current and future variants of the COVID-19 virus. Oravax’s VLP vaccine technology is highly scalable and easily transferable. 

“An oral COVID-19 vaccine would eliminate several barriers to rapid, widescale distribution, potentially enabling people to administer the vaccine themselves at home,” Nadav Kidron, CEO of Oramed, said in a statement.  

“Following this Phase 1 trial, our intention is to move forward with a Phase 2/3 trial for emergency use approval in relevant countries,” he added.

Sign up for the BioTuesdays weekly newsletter

Get the latest news on the healthcare industry’s corporate and clinical developments, executive moves, and market updates. Every Tuesday, in your inbox.